Assaid Najlaa, Arich Soukaina, Charoute Hicham, Akarid Khadija, Ezzikouri Sayeh, Maaroufi Abderrahmane, Sarih M'hammed
Service de Parasitologie et des Maladies Vectorielles, Institut Pasteur du Maroc, Place Louis Pasteur, Casablanca 20360, Morocco.
Health and Environment Laboratory, Molecular Genetics and Immunophysiopathology Research Team, Aïn Chock Faculty of Sciences, University of Hassan II Casablanca (UH2C), Casablanca 20100, Morocco.
Vaccines (Basel). 2022 Mar 18;10(3):465. doi: 10.3390/vaccines10030465.
Data about the duration of antibodies after vaccination show that the protection against SARS-CoV-2 infection begins to decline over time. This study aims to determine anti-SARS-CoV-2 anti-S IgG levels in healthcare workers five months after the second vaccination dose. We collected samples from 82 participants who were fully vaccinated with ChAdOx1 nCoV-19 or BBIBP-CorV. We assessed anti-SARS-CoV-2 IgG antibodies using a Euroimmun ELISA and an Abbott Architect ™ SARS-CoV-2 IgG test. Of the 82 participants, 65.85% were seropositive for IgG using ELISA, and 86.59% were positive for IgG according to the Abbott Architect ™ test. Individuals vaccinated with the ChAdOx1 nCoV-19 vaccine had a median anti-S1 antibody level of 1.810 AU/mL [interquartile range (IQR), 1.080-3.7340] and 171.7 AU/mL [79.9-684.6] according to the Euroimmun ELISA and Abbott Architect test, respectively. These tests indicated that people vaccinated with BBIBP-CorV had a median anti-S1 antibody level of 1.840 AU/mL [0.810-2.960] and 126.7 AU/mL [54.9-474.3], respectively. Statistical analysis showed no significant difference between the positivity rates of the vaccinated individuals, either for gender or for age. In addition, we found no significant difference between the two vaccines. Our study provides information on the longevity of the anti-SARS-CoV-2 IgG antibodies in people at least five months after vaccination.
关于接种疫苗后抗体持续时间的数据表明，针对SARS-CoV-2感染的保护作用会随着时间的推移而开始下降。本研究旨在确定医护人员在接种第二剂疫苗五个月后的抗SARS-CoV-2抗S IgG水平。我们从82名接种了ChAdOx1 nCoV-19或BBIBP-CorV疫苗的参与者中收集了样本。我们使用Euroimmun ELISA和雅培Architect™ SARS-CoV-2 IgG检测来评估抗SARS-CoV-2 IgG抗体。在这82名参与者中，使用ELISA检测IgG呈血清阳性的比例为65.85%，根据雅培Architect™检测，IgG呈阳性的比例为86.59%。接种ChAdOx1 nCoV-19疫苗的个体，根据Euroimmun ELISA检测，抗S1抗体水平中位数为1.810 AU/mL[四分位间距（IQR），1.080 - 3.7340]，根据雅培Architect检测为171.7 AU/mL[79.9 - 684.6]。这些检测表明，接种BBIBP-CorV疫苗的人抗S1抗体水平中位数分别为1.840 AU/mL[0.810 - 2.960]和126.7 AU/mL[54.9 - 474.3]。统计分析表明，接种疫苗个体的阳性率在性别或年龄方面均无显著差异。此外，我们发现两种疫苗之间没有显著差异。我们的研究提供了关于接种疫苗至少五个月后人群中抗SARS-CoV-2 IgG抗体持久性的信息。
